We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: psoriasis
MedXY News
EnglishTag

psoriasis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Reversing Epigenetic Aging in Psoriasis: The Impact of Tildrakizumab over 52 Weeks
DermatologyIL-23 inhibitiontildrakizumab

Reversing Epigenetic Aging in Psoriasis: The Impact of Tildrakizumab over 52 Weeks

By MedXY|Aug 26, 2026

This study demonstrates that tildrakizumab, an IL-23 inhibitor, partially reverses accelerated epigenetic aging in psoriasis patients, highlighting a novel aspect of biologic therapy beyond skin inflammation control.

Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship
DermatologyAntibioticsbiologics

Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship

By MedXY|Nov 17, 2025

A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting

Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs
DermatologyIcotrokinraIL-23

Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs

By MedXY|Nov 10, 2025

Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and

Mediterranean Diet as Adjunct Therapy in Psoriasis: Insights from the MEDIPSO Randomized Clinical Trial
DermatologyinflammationMediterranean diet

Mediterranean Diet as Adjunct Therapy in Psoriasis: Insights from the MEDIPSO Randomized Clinical Trial

By MedXY|Oct 9, 2025

A 16-week Mediterranean diet intervention significantly reduced psoriasis severity and improved metabolic markers in patients with mild to moderate disease, suggesting diet’s role as adjunctive therapy in psoriasis management.

Icotrokinra: A Promising Oral IL-23 Inhibitor Outperforms JAK Inhibitor in Psoriasis Phase 3 Trials
Allergy & ImmunologydeucravacitinibIcotrokinra

Icotrokinra: A Promising Oral IL-23 Inhibitor Outperforms JAK Inhibitor in Psoriasis Phase 3 Trials

By MedXY|Oct 9, 2025

In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psorias

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities